Translating R&D concepts into confident decisions

QSP has enormous potential to improve biopharmaceutical R&D and inform decision-making across the drug development process. QSP combines computational modeling and experimental data to examine the relationships between a drug, the biological system, and the disease process.  With the ability to leverage vast amounts of biological and pharmacological data, QSP enables the understanding of disease pathophysiology, to identify and test therapeutic strategies in virtual trials with virtual patients.

Certara has differentiated its approach to QSP by building robust, regulatory-ready software platforms for reproducible model development.  Today, those platforms are available for immunogenicity, immuno-oncology, and next, neurodegenerative diseases.  The software is available in proprietary and proven editor tool, with an easy-to-use interface, that delivers models and model results that are reproducible.  This unique approach has been shared with US, EU and Japanese regulators, all committed to advancing the use of QSP in drug discovery, development and regulatory review.

 

Download QSP Fact Sheet

Understanding the Impact of Immunogenicity
  • Innovation in biologic development has led to a marked increase in the approvals of protein-based therapeutics for a range of diseases. Despite the success of biologics, immunogenicity (IG) or the tendency to trigger an unwanted immune response remains an inherent and major challenge. As a result, Certara developed a QSP software platform with support from the seven members of its QSP IG Consortium to predict the IG of biologics and its impact on efficacy and safety in diverse patient populations.Certara’s IG Simulator, built in a unique regulatory-ready platform supports decision-making from discovery through clinical.  It can take FIH data to design Phase II/III trials, predict impact of disease and co-medication, extrapolate to new populations, and predict if IG can be managed by dosing.  The robustness of this groundbreaking model will facilitate compound prioritization and informing go/no decisions for biologics developers.

    Based on our work in IG, we are also rapidly advancing a new QSP platform for COVID-19 vaccines.  The Certara QSP COVID-19 Simulator will be used to provide dosing recommendations across multiple patient populations.

Download white paper
Tackling the most complex challenges with consulting services

In its July 2020 workshop, the US FDA described this modeling & simulation technology as shifting from “justifying the value of QSP”—to “best practices” implementation. QSP can help answer questions about the most novel compounds and modalities, combination therapy, initial dosing for first-of-its kind therapies, and other vexing development situations:

  • In a given biological pathway, what is the best target and modality for pharmacological intervention to treat a given disease
  • How can we improve the therapeutic effectiveness of an existing drug through combination therapy
  • Can we predict human response (dose) to a novel mechanism based on preclinical data
  • How can we better understand the underlying pathophysiology to identify druggable pathways?
  • Can we predict the effect of a drug in a special population/other indication
  • How can QSP support translation, product differentiation and utility of biomarkers
  • Can we individualize dosing regimen based on patient characteristics
  • How can we optimize clinical trials by accounting for pharmacodynamics interactions with comedications and genotypes

Certara is currently providing QSP consulting services and regulatory support to address the above questions, in therapeutic areas including oncology, vaccines, neurology, CNS, hematology, autoimmune disorders, rare disease, dermatology and gene therapy.

Browse our library of QSP papers
Advancing Combination Immuno-oncology Therapy

While Immuno-oncology has delivered on its promise for treating a wide range of cancers in targeted populations, the expansion of that success through combination therapy has been more elusive.  QSP is well suited to address this challenge, by understanding and integrating the complex dynamic factors determining efficacy that can lead to better combinations and dosing regimens for a wider group of patients.

Working with a consortium of six leading pharmaceutical companies, Certara has developed a QSP IO Simulator that will enable exploration of different therapeutic combinations, even drugs using different modalities, within virtual populations. The Simulator incorporates compounds’ pharmacokinetics, target binding, and mechanisms of action as well as existing knowledge on the underlying tumor and immune system biology to predict clinical results for novel combinations, and complex biologics such as bi-specifics.

Contact us about your project
Piet van der Graaf, PharmD, PhD Senior Vice President, Quantitative Systems Pharmacology

With over 20 years of experience working in the pharmaceutical industry at Sanofi and Pfizer, Piet brings considerable skill and experience to QSP projects and contributes to the strategic development of Certara.  He is also Editor-in-Chief of CPT: Pharmacometrics & Systems Pharmacology.

Andrzej Kierzek, PhD Head of Systems Modeling

With 25 years of experience in computational biology. Andrzej has published models and software for analysis of molecular network dynamics and constraint based modelling of genome scale metabolic networks. Currently, his scientific work focuses on immuno-oncology and immunogenicity.  He is a visiting Professor of Systems Biology at Surrey.

Hugo Geerts, PhD Head of QSP Neurosciences

In addition to 18 years of mechanism-based QSP modeling in Neurology and Psychiatry as co-founder of In Silico Biosciences, Hugo has 20 years of experience in drug discovery and development as a Research Fellow at the Janssen Research Foundation laboratoria in Beerse, Belgium.  At Certara, he leads a new Certara QSP consortium focused on neurodegenerative diseases.

Back to top